How Many Points Is a Shot of Wegovy?

Marco Rubio is executing the president’s wishes around the world, even when they contradict his past beliefs. What’s his long game? By Eric Martin and Nancy CookSee omnystudio.com/listener for privacy information. 

Behind-the-scenes with the skeleton crew that’s unwinding every last bit of the airline—until there’s nothing left. By Drake Bennett and Sri Taylor See omnystudio.com/listener for privacy information. 

America’s elders need more places to live, but even in liberal enclaves that recognize the problem, developers are facing the fiercest foes of all: America’s elders. By Charley LockeSee omnystudio.com/listener for privacy information. 

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ... Show More

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More

The latest fad diet isn’t a diet, it’s a shot — Ozempic is being called a miracle weight loss drug, and it’s disrupting Weight Watchers. LVMH is proud of their pricey perfume, and they are selling more than ever thanks to their Rihanna-aided storytelling. And H&R Block vs. TurboT ... Show More

A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ... Show More

<p>WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the ... Show More

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show More

Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More